Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis - Takeaways - MDSpire

Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis

  • By

  • Shrila Banerjee

  • Abul Kalam Azad Mandal

  • June 11, 2026

  • 0 min

Share

  • 1

    Epigallocatechin-3-gallate (EGCG) exhibits anticancer properties, reducing cell viability and migration in breast cancer cells.

  • 2

    EGCG induces apoptosis and G0/G1 cell cycle arrest in MDA-MB-231 breast cancer cells, demonstrating its tumor-suppressive effects.

  • 3

    The study confirmed that EGCG modulates miR-27a-3p expression, which is linked to breast cancer progression and metastasis.

  • 4

    EGCG affects key Wnt/β-catenin pathway markers, leading to the suppression of oncogenic signaling in breast cancer.

  • 5

    The findings support the potential of EGCG as a therapeutic agent targeting the miR-27a/Wnt/β-catenin pathway in breast cancer.

Original Source(s)

Epigallocatechin-3-gallate suppressed breast oncogenesis via the miR-27a/Wnt/β-catenin pathway axis

  • by Shrila Banerjee, Abul Kalam Azad Mandal

  • June 11, 2026

Related Content

The unheard pain: why patient-related barriers remain the weakest link in cancer pain management

Development and validation of an interpretable machine learning model for predicting 5-year recurrence in breast cancer

Bulk and single-cell RNA sequencing data identified HMGB3 of chromatin regulators as a breast cancer biomarker associated with the cell cycle